



Quanta appoints Dr Peter Kerr and Dr Elizabeth Lindley to its Medical Advisory Board

Alcester, Warwickshire, UK, 20 October 2015: Quanta Fluid Solutions Ltd (“Quanta” or the “Company”), a pioneering developer of advanced haemodialysis systems, today announces the appointment of Dr Peter Kerr and Dr Elizabeth Lindley to the Company’s Medical Advisory Board, with immediate effect.

Dr Peter Kerr has a long and established career in nephrology and is a strong advocate of home-dialysis. He completed his undergraduate degree in medicine at Monash University, Melbourne, later returning to work there as a Nephrologist and, since 2006, he has led the department as Professor and Director of Nephrology. Dr Kerr also has several honorary appointments at other hospitals, societies and patient groups. He has been a member of several Australian State Government committees on health and dialysis and has authored or co-authored over 230 journals and articles. He has been Editor-in-Chief of the Asian Pacific Journal of Nephrology since 2010.

Dr Elizabeth Lindley is a Specialist Clinical Scientist working in the Department of Renal Medicine at the Leeds Teaching Hospitals NHS Trust. She is Co-Lead for the Renal Theme of the NIHR Devices for Dignity Healthcare Technology Co-operative and a facilitator for the UK Renal Technology course in Bradford. Dr Lindley is currently moderator of the RenalPro e-mail discussion forum for renal care professionals, a member of the European Renal Association’s Best Practice Advisory Board (ERBP) and the UK Renal Association’s Clinical Practice Guidelines committee. Her interests include body composition monitoring, management of renal anaemia and bone disease, preservation of kidney function, quality assurance in dialysis and promotion of shared care.

John E. Milad, Chief Executive Officer of Quanta, commented: *“We are very pleased to welcome Dr Peter Kerr and Dr Elizabeth Lindley to our Medical Advisory Board. Our ability to attract such influential thought-leaders provides strong validation of SC+ and our mission. Their careers and achievements span international markets, national healthcare systems, academia and patient groups, and include notable contributions to medical and industry journals. Across all this, their primary focus has always been the provision of best practice dialysis techniques and patient care. We look forward to working with them as we promote SC+ to expand the possibilities and availability of patient-led care.”*

Commenting on his appointment Dr Peter Kerr said: *“It has long been known and supported with scientific evidence that, for a certain groups of patients, patient-led care—whether at home or in centre—leads to better outcomes. Quanta’s SC+ is targeting that very group and I look forward to supporting the further development and international proliferation of this innovative and important medical device.”*

Commenting on her appointment Dr Elizabeth Lindley said: *“The renal team at Devices for Dignity has supported Quanta’s innovative ideas and vision of a truly patient-centred*

machine since the initial concept of the SC+. Now the device has been realised, I hope that it will soon be helping to increase independence and quality of life for haemodialysis patients.”

-ENDS-

For more information about Quanta, please contact:

Quanta

John E. Milad,
Chief Executive Officer

T: +44 (0)1789 400043
E: john.milad@quantafs.com

Consilium Strategic Communications

Amber Fennell / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708
E: quanta@consilium-comms.com

About SC+

SC+ is designed to bring flexibility to dialysis patients and physicians by supporting all treatment regimens, from nurse-assisted care and patient self-care in-centre, to home haemodialysis. SC+ is the only portable, compact haemodialysis system capable of operating at the higher flow rates typically used to treat patients in-centre by traditional machines. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge.

About Quanta

Quanta is developing advanced haemodialysis systems for use in the clinic and the home. The Company has recently obtained CE Mark for its flagship product SC+, which is a portable, compact cartridge-based haemodialysis system. SC+ is designed to offer ease-of-use and flexibility whilst facilitating self-care and supporting dialysis patients across the entire continuum of care.

Quanta is privately owned and based in Alcester, UK. The Company was founded in 2008 as a spin out from the FTSE 100 engineering company IMI plc, with funding provided by a group of leading venture capital investors specialised in healthcare: NBGI Ventures, Wellington Partners, Seroba Kernel and b-to-v Partners, and more recently ALIAD, Seventure Partners and Kuwait Life Sciences Company.

Quanta is dedicated to creating a paradigm shift in renal care and to improving the lives of dialysis patients.

For more information please visit: www.quantafs.com.

About End Stage Renal Disease and Haemodialysis

Lifestyle choices, modern diet and increased life expectancy are all negatively impacting renal health across the globe and End Stage Renal Disease affects millions of patients worldwide. Haemodialysis is a life-saving treatment delivered to an estimated 2 million people globally— with this figure expected to double in the next decade.

At present, haemodialysis is primarily provided by specialist clinics and centres. However this means that the patient is not in control of when they can dialyse. It is clinically proven that more regular dialysis improves outcomes and quality of life for the patient, and a number of studies have shown that 30-40% of patients would be capable of performing self-dialysis.

Issues of patient benefit, cost and clinic capacity are driving the growth of home and self-care modalities of haemodialysis, but a major factor limiting the growth of self-care and home haemodialysis is the lack of convenient, portable and easy-to-use dialysis systems. SC+ addresses these issues and puts the patient at the centre, allowing them to take greater control of their treatment.